HomeUSALindus Health Raises $55M in Series B Funding

Lindus Health Raises $55M in Series B Funding

-

Co-Founders Michael Young, Nik Haldimann, and Meri Beckwith.

Lindus Health, a NYC-based company that enables customers to run clinical trials, raised $55M in Series B funding.

The round was led by new investor Balderton Capital, with support from Visionaries Club and existing investors Creandum, Firstminute, and Seedcamp.

Co-founded by Michael Young, Nik Haldimann, and Meri Beckwith, Lindus Health provides fully integrated CRO services and in-house trial management technology.

The company intends to use the funds to further develop its proprietary AI technology and eClinical platform, Citrus™, to optimize study design, automate central monitoring of study data, enable instant biostatistics, and more. Launched in 2021, Lindus Health has operated a total of 42 end-to-end clinical trials, making an impact across a broad range of market segments including psychiatry, diagnostics, and respiratory health. The company has enrolled over 36,000 patients in their trials across North America and Europe, including collaborations with Aktiia on a 7,500-patient device study and Pharmanovia on a Phase IV trial for insomnia.

The company is backed by a strategic advisory board including Robert S. Langer, founder of Moderna and over 40 other biotechnology companies, and Tim Garnett, former CMO of Eli Lilly, amongst others.

FinSMEs

22/01/2025

THE DAILY NEWSLETTER - SIGNUP